Bright Minds Biosciences (DRUG) News Today $38.65 -0.46 (-1.18%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% - Time to Sell?Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 4.3% - What's Next?December 19 at 3:09 AM | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Upgraded by Baird R W to Strong-Buy RatingBaird R W upgraded shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Monday.November 27, 2024 | marketbeat.comBright Minds Biosciences: Promising Pipeline and Strategic Positioning Justify Buy RatingNovember 26, 2024 | markets.businessinsider.comBaird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform RecommendationNovember 26, 2024 | msn.comBright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual MeetingNovember 22, 2024 | finance.yahoo.comBright Minds Biosciences to Present Novel Epilepsy DataNovember 22, 2024 | markets.businessinsider.comBright Minds Biosciences participates in a conference call with TruistNovember 20, 2024 | markets.businessinsider.comBright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementNovember 4, 2024 | globenewswire.comBright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market PotentialOctober 30, 2024 | seekingalpha.comShort Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 1,274.9%Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,170,000 shares, an increase of 1,274.9% from the September 30th total of 85,100 shares. Approximately 38.2% of the company's stock are short sold. Based on an average trading volume of 2,890,000 shares, the short-interest ratio is currently 0.4 days.October 25, 2024 | marketbeat.comSteven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc SharesOctober 24, 2024 | uk.finance.yahoo.comCormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences SharesOctober 23, 2024 | finance.yahoo.comBright Minds and Firefly Neuroscience Renew CollaborationOctober 22, 2024 | markets.businessinsider.comBright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH studyOctober 22, 2024 | markets.businessinsider.comWhat's Going On With Bright Minds Biosciences Stock?October 22, 2024 | msn.comBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataOctober 21, 2024 | globenewswire.comMarketBeat Week in Review – 10/14 - 10/18 (DRUG)Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.October 19, 2024 | marketbeat.comBright Minds rebounds after $35M private placementOctober 18, 2024 | msn.comWhat's Going On With Bright Minds Biosciences Stock Friday?October 18, 2024 | msn.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Major Shareholder Cormorant Asset Management, Lp Acquires 372,591 SharesOctober 18, 2024 | insidertrades.comBright Minds Biosciences Announces US$35 Million Non-Brokered Private PlacementOctober 18, 2024 | globenewswire.comCormorant Asset Management, Lp Purchases 372,591 Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG) StockBright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 372,591 shares of the stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average price of $5.53 per share, for a total transaction of $2,060,428.23. Following the completion of the acquisition, the insider now directly owns 825,000 shares of the company's stock, valued at $4,562,250. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.October 17, 2024 | marketbeat.comPerceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences IncOctober 16, 2024 | finance.yahoo.comBright Minds Biosciences Inc Ordinary SharesOctober 16, 2024 | morningstar.comBright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain modelsOctober 16, 2024 | globenewswire.comBright Minds Biosciences Stock Surges Almost 1,500%Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.October 16, 2024 | marketbeat.comBiotech stock tumbles after unexplained 1,446% gainOctober 16, 2024 | msn.comBright Minds Biosciences announces participation in upcoming scientific conferences and partnering eventsOctober 3, 2024 | globenewswire.comBright Minds Biosciences Inc Ordinary Shares DRUGOctober 3, 2024 | morningstar.comBright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thSeptember 19, 2024 | globenewswire.comBright Minds Biosciences launches Phase II trial of absence epilepsy treatmentSeptember 14, 2024 | msn.comBright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic EncephalopathySeptember 12, 2024 | prnewswire.comBright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D EffortsAugust 16, 2024 | benzinga.comMedical journal retracts three articles related to MDMA for PTSDAugust 12, 2024 | msn.comPsyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And MoreJanuary 12, 2024 | msn.comBright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementDecember 6, 2023 | finance.yahoo.comPsyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & MoreNovember 12, 2023 | msn.comBright Minds Biosciences Inc. (DRUG.CN)November 12, 2023 | finance.yahoo.comBright Minds Biosciences Stock (NASDAQ:DRUG) Dividends: History, Yield and DatesOctober 25, 2023 | benzinga.comDRUG Bright Minds Biosciences Inc.August 18, 2023 | seekingalpha.comBright Minds stock rallies ahead of conference call to discuss Phase 1 dataAugust 8, 2023 | msn.comBright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101August 8, 2023 | finance.yahoo.comBright Minds reports results from trial to treat refractory epilepsiesAugust 7, 2023 | msn.comCybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical TrialsJuly 24, 2023 | benzinga.comBright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101July 20, 2023 | finance.yahoo.comBright Minds Biosciences Stock (NASDAQ:DRUG), Short Interest ReportJuly 12, 2023 | benzinga.comBright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ ComplianceJuly 11, 2023 | msn.comBright Minds Biosciences: Bright Minds Announces Effective Date of Share ConsolidationJuly 11, 2023 | finanznachrichten.deBright Minds Biosciences: Bright Minds Announces Proposed Share ConsolidationJune 22, 2023 | finanznachrichten.deBright Minds Announces Proposed Share ConsolidationJune 22, 2023 | finance.yahoo.com Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. DRUG Media Mentions By Week DRUG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRUG News Sentiment▼0.670.60▲Average Medical News Sentiment DRUG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRUG Articles This Week▼10▲DRUG Articles Average Week Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dianthus Therapeutics News Today Rapport Therapeutics News Today Autolus Therapeutics News Today Oculis News Today Cullinan Therapeutics News Today Prothena News Today Entrada Therapeutics News Today Arbutus Biopharma News Today Tectonic Therapeutic News Today Stoke Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRUG) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts